What is IPF Phase III CAPACITY 2 (pirfenidone)?

Category: Others

true

Generic name: Pirfenidone

The CAPACITY 2 trial was a Phase III, placebo controlled trial of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis. NCT00287716

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 0

Commonly reported side effects and conditions associated with IPF Phase III CAPACITY 2 (pirfenidone)

Side effect Patients
Decreased respiratory function 1

Dosages

Based on patients currently taking IPF Phase III CAPACITY 2 (pirfenidone)

Dosage Patients
265 mg twice daily 1

Duration

Currently taking IPF Phase III CAPACITY 2 (pirfenidone)

Duration Patients
2 - 5 years 1

What people switch to and from

Patients started taking IPF Phase III CAPACITY 2 (pirfenidone) after stopping:

Treatment Patients
Formoterol-mometasone (Dulera) 1
Nintedanib (Ofev) 1

Patients stopped taking IPF Phase III CAPACITY 2 (pirfenidone) and switched to:

Treatment Patients
Nintedanib (Ofev) 1
Last updated:
There are no evaluations for IPF Phase III CAPACITY 2 (pirfenidone).